2 September 2020
With Covid-19 cases seemingly on the increase once again, both in the UK and overseas, AIM listed Avacta has announced that it has entered into an agreement with Abingdon Health for the manufacture of Avacta's saliva-based rapid SARS-Cov-2 antigen test as part of its expansion of its manufacturing capacity. Avacta is developing a rapid test strip for use with patient saliva which aims to provide a result in a matter of minutes indicating whether the patient has coronavirus. The agreement with Abingdon will provide additional manufacturing capacity providing several million tests per . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
